Seroatlas · Human Serome Atlas

YRDC

Threonylcarbamoyl-AMP synthase

Also known as: FLJ23476, IRIP, SUA5, YRDC_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q86U90
Gene
YRDC
Ensembl
ENSG00000196449
Chromosome
1
Canonical length
279 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
Subcellular location
Mitochondria

OverviewNCBI Gene

Enables L-threonylcarbamoyladenylate synthase. Involved in tRNA threonylcarbamoyladenosine modification. Acts upstream of or within negative regulation of transport. Is active in mitochondrion. Implicated in Galloway-Mowat syndrome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

279 residues, UniProt reviewed canonical sequence.

>Q86U90|YRDC
     1  MSPARRCRGM RAAVAASVGL SEGPAGSRSG RLFRPPSPAP AAPGARLLRL PGSGAVQAAS
    61  PERAGWTEAL RAAVAELRAG AVVAVPTDTL YGLACAASCS AALRAVYRLK GRSEAKPLAV
   121  CLGRVADVYR YCRVRVPEGL LKDLLPGPVT LVMERSEELN KDLNPFTPLV GIRIPDHAFM
   181  QDLAQMFEGP LALTSANLSS QASSLNVEEF QDLWPQLSLV IDGGQIGDGQ SPECRLGSTV
   241  VDLSVPGKFG IIRPGCALES TTAILQQKYG LLPSHASYL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against YRDC can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.34
Highest tissue expression
47 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 47 nTPM
  • testis: 16 nTPM
  • esophagus: 15 nTPM
  • urinary bladder: 15 nTPM
  • skin: 15 nTPM
  • pancreas: 13 nTPM

Single-cell type

  • extravillous trophoblasts: 56 nCPM
  • differentiating spermatogonia: 48 nCPM
  • suprabasal keratinocytes: 47 nCPM
  • syncytiotrophoblasts: 45 nCPM
  • basal keratinocytes: 45 nCPM
  • migrating cytotrophoblasts: 45 nCPM

Immune cell

  • basophil: 8.8 nTPM
  • naive CD4 T-cell: 1 nTPM
  • naive CD8 T-cell: 1 nTPM
  • T-reg: 1 nTPM
  • memory CD4 T-cell: 0.9 nTPM
  • plasmacytoid DC: 0.9 nTPM

Brain region

  • cerebellum: 14 nTPM
  • pons: 13 nTPM
  • hypothalamus: 12 nTPM
  • cerebral cortex: 12 nTPM
  • midbrain: 11 nTPM
  • medulla oblongata: 11 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about YRDC.

Disease | AllUniProt

Conditions YRDC is implicated in, by any mechanism.

Disease | GeneticClinVar

4 pathogenic / likely-pathogenic of 120 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Galloway-Mowat syndrome 10

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.32
gnomAD pLI
0
gnomAD missense Z
0.1
DepMap mean gene effect
-1.57
DepMap dependency class
common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

  • Threonylcarbamoyl-AMP synthase-like domain
  • DHBP synthase RibB-like alpha/beta domain superfamily
  • Threonylcarbamoyl-AMP synthase, SUA5
  • Telomere recombination

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of YRDC in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads YRDC as an antibody target. Whether an autoantibody or antibody against YRDC could matter depends on whether native YRDC is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

YRDC is annotated at the cell surface, where native YRDC is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label YRDC as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/YRDC. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...